Antibody-based therapies are some of the most advanced medications for fighting cancer. Their delivery is far more progressive than any other cancer fighting medication of the past. Seattle Genetics, an oncology biotech company, is a worldwide leader in cancer research. This company has been around since the late 1990s, and it has grown dramatically thanks to Clay Siegall. This guy just so happens to be the company’s founder and CEO. Siegall is looking to take Seattle Genetics even farther by handling the international marketing of its advanced drugs. Instead of selling to a much larger company, Seattle Genetics is looking to further continue its growth by handling all of the international marketing complexities. International marketing is crucial, and when you control your very own marketing rights, you can control your very own destiny.
ADCETRIS, the company’s flagship drug, is one of the most successful antibody drug conjugates to date, and it has brought in hundreds of millions of dollars over the past few years. As of today, ADCETRIS is being distributed to 65 countries around the world. This new generation of advanced therapies deliver a cell-killing blow to cancerous cells within the body without harming any of the good cells. This drastically cuts down on sickening side effects, which come as a result of taking cancer medications. Seattle Genetics dominates the cancer research landscape. It’s located in Bothell, Washington, and it has nearly 1,000 employees. With such huge success, the company will be looking to add another 250 employees to its roster.
On the other hand, Dr. Clay Siegall is a man of many acts. He’s a doctor, a scientist, a mentor and a philanthropist. The guy has a Ph.D in Genetics from George Washington University as well as a B.S. in Zoology from the University of Maryland. Siegall knows just how deadly cancer can be as his father struggled with the disease for many years. This actually drew the line in the sand and as of this day, he has done everything in his power to save as many lives as possible.